Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Payables (2016 - 2025)

Veracyte (VCYT) has disclosed Payables for 14 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • Quarterly Payables fell 46.8% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, down 46.8% year-over-year, with the annual reading at $4.6 million for FY2025, 46.8% down from the prior year.
  • Payables hit $4.6 million in Q4 2025 for Veracyte, down from $5.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $15.7 million in Q1 2025 to a low of $4.6 million in Q4 2025.
  • Historically, Payables has averaged $10.9 million across 5 years, with a median of $11.4 million in 2022.
  • Biggest five-year swings in Payables: soared 479.76% in 2021 and later crashed 46.8% in 2025.
  • Year by year, Payables stood at $12.4 million in 2021, then dropped by 3.63% to $11.9 million in 2022, then grew by 8.66% to $12.9 million in 2023, then plummeted by 33.29% to $8.6 million in 2024, then plummeted by 46.8% to $4.6 million in 2025.
  • Business Quant data shows Payables for VCYT at $4.6 million in Q4 2025, $5.5 million in Q3 2025, and $11.4 million in Q2 2025.